Local indices are trading on a firm note in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 234.60 points or 0.49% at 48,408.66. The Nifty 50 index was up 74.80 points or 0.53% at 14,221.05.
The S&P BSE Mid-Cap index was up 1.01%. The S&P BSE Small-Cap index was up 1.05%.
The market breadth, indicating the overall health of the market, is strong. On the BSE, 1769 shares rose and 368 shares fell. A total of 79 shares were unchanged.
Stocks in news:
Maruti Suzuki India rose 0.4%. Maruti Suzuki India said total production increased to 1.55 lakh vehicles in December 2020, from 1.15 lakh vehicles in December 2019.
Lupin receives approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP
Posted On: 2021-01-06 03:54:17 (Time Zone: Arizona, USA)
Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.
Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).
Lupin has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of
Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.
Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the
treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and
intestinal infections), and certain type of pneumonia (pneumocystis-type).
Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales of
approximately USD 19 million in the U.